Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia

Authors

Priya S Kishnani, Duke University
Cheryl Rockman-Greenberg, University of Manitoba
Frank Rauch, McGill University
M Tariq Bhatti, Duke University
Scott Moseley, Alexion Pharmaceuticals, Inc.
Andrew E Denker, Alexion Pharmaceuticals, Inc.
Eric Watsky, Alexion Pharmaceuticals, Inc.
Michael P Whyte, Washington University School of Medicine in St. Louis

Journal

Bone

Publication Date

4-1-2019

Volume

121

First Page

149

Last Page

162

Document Type

Open Access Publication

DOI

10.1016/j.bone.2018.12.011

Rights and Permissions

Kishnani PS, Rockman-Greenberg C, Rauch F, Bhatti MT, Moseley S, Denker AE, Watsky E, Whyte MP. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019 Apr;121:149-162. doi: 10.1016/j.bone.2018.12.011. © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).T

Recommended Citation

Kishnani, Priya S; Rockman-Greenberg, Cheryl; Rauch, Frank; Bhatti, M Tariq; Moseley, Scott; Denker, Andrew E; Watsky, Eric; and Whyte, Michael P, "Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia." Bone. 121, 149 - 162. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/9764